Sign In

News Story

Merck Foundation invests $1.99M in our global patient navigation work

​Grant bolsters ACS patient navigation efforts in Africa

The American Cancer Society’s Global Cancer Control efforts got a boost today with the announcement of a five-year, $1.99 million grant to improve support and access to care for people living with cancer in low- and middle-income countries. The funding will support our patient navigation work, primarily in sub-Saharan Africa. 

More than 70% of the 9 million cancer-related deaths worldwide are in resource-limited settings, where patients face barriers to timely diagnosis and high-quality care. Patient navigators play an important role in supporting patients from diagnosis through treatment. 

Our global navigation initiative is focused on helping our partners build their capacity to deliver this important work. We focus on sharing what we know with our partners – best practices learned in more than 100 years of fighting cancer – and helping them apply these lessons in ways that are relevant and attainable even in low-resource settings.  

The grant will help ACS fortify our patient navigation program at Kenyatta National Hospital and adapt it for the Uganda Cancer Institute, which serves about 200 people a day and has a high need for navigation services. This grant is a first step toward expansion of patient navigation programs to help more patients in resource-limited settings receive timely, high-quality care. As part of this effort, ACS will develop a comprehensive guide and toolkit to develop and implement patient navigation programs, designed specifically for health facilities in low- and middle-income countries. Lessons learned from collaborating with hospitals in Kenya and Uganda will be incorporated into this guide, which ACS will pilot in health institutions in Asia and Latin America.

Hear from Gladys Mukosi, a clinical navigator at Kenyatta National Hospital, and find out more about the navigation project on the MSD Corporate Responsibility website. Merck & Co., Inc., headquartered in Kenilworth, NJ, is known as MSD outside of the U.S. and Canada. It is one of the largest pharmaceutical companies in the world.


back to top